The drug created by artificial intelligence showed signs of effectiveness in the treatment of severe lung disease. This was reported by the biotechnological company Insilico Medicine, writes Bloomberg.
According to the startup, this is the first time when the “generated” remedy has passed the intermediate stage of clinical trials.
The drug called Rentosertib (Rentosertib) contributed to an improvement in the function of the lungs in a small group of patients with idiopathic pulmonary fibrosis – a disease in which the scarring of the lungs complicates breathing. The analysis of biomarkers showed that it works exactly according to the AI idea – reduces protein, which is allegedly related to the disease.
InSilico Medicine is developing a plan of more large -scale tests to confirm the effect of rent -vertebib. The company intends to receive reviews from regulators and potential pharmaceutical partners.
The data will serve as a foundation for more than 30 Insilico programs and help to improve the model of artificial intelligence, Zhavoronkov noted.
The study was conducted 12 weeks. 71 patients took part in it – all from China. Some have worsened the condition, others were faced with liver problems.
According to Zhavoronkov, side effects can be controlled, and the drug is “safe enough.”
Be in the know! Subscribe to Telegram.
Source: Cryptocurrency
I am an experienced journalist and writer with a career in the news industry. My focus is on covering Top News stories for World Stock Market, where I provide comprehensive analysis and commentary on markets around the world. I have expertise in writing both long-form articles and shorter pieces that deliver timely, relevant updates to readers.
